首页 > 最新文献

Annals of Thoracic Surgery最新文献

英文 中文
Goal-directed Perfusion Strategy During Pediatric Cardiac Operation: Further Detail to Enhance Its Clinical Applicability.
IF 3.6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-02-19 DOI: 10.1016/j.athoracsur.2025.01.031
Feng Long, Ronghua Zhou
{"title":"Goal-directed Perfusion Strategy During Pediatric Cardiac Operation: Further Detail to Enhance Its Clinical Applicability.","authors":"Feng Long, Ronghua Zhou","doi":"10.1016/j.athoracsur.2025.01.031","DOIUrl":"https://doi.org/10.1016/j.athoracsur.2025.01.031","url":null,"abstract":"","PeriodicalId":50976,"journal":{"name":"Annals of Thoracic Surgery","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143473320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sorting Out the Pieces of Fragmented Lung Cancer Care.
IF 3.6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-02-19 DOI: 10.1016/j.athoracsur.2025.01.030
Juan M Farina, Jonathan D'Cunha
{"title":"Sorting Out the Pieces of Fragmented Lung Cancer Care.","authors":"Juan M Farina, Jonathan D'Cunha","doi":"10.1016/j.athoracsur.2025.01.030","DOIUrl":"https://doi.org/10.1016/j.athoracsur.2025.01.030","url":null,"abstract":"","PeriodicalId":50976,"journal":{"name":"Annals of Thoracic Surgery","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143473327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enhancing Graft Patency in Coronary Artery Bypass Grafting: Fluid Mechanics, Anastomotic Techniques, and Flow Dynamics.
IF 3.6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-02-19 DOI: 10.1016/j.athoracsur.2025.01.032
Yasunari Hayashi, Toshiaki Ito
{"title":"Enhancing Graft Patency in Coronary Artery Bypass Grafting: Fluid Mechanics, Anastomotic Techniques, and Flow Dynamics.","authors":"Yasunari Hayashi, Toshiaki Ito","doi":"10.1016/j.athoracsur.2025.01.032","DOIUrl":"https://doi.org/10.1016/j.athoracsur.2025.01.032","url":null,"abstract":"","PeriodicalId":50976,"journal":{"name":"Annals of Thoracic Surgery","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143473315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editor's Choice
IF 3.6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-02-18 DOI: 10.1016/S0003-4975(25)00022-0
{"title":"Editor's Choice","authors":"","doi":"10.1016/S0003-4975(25)00022-0","DOIUrl":"10.1016/S0003-4975(25)00022-0","url":null,"abstract":"","PeriodicalId":50976,"journal":{"name":"Annals of Thoracic Surgery","volume":"119 3","pages":"Page A8"},"PeriodicalIF":3.6,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143429364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Society Board 协会理事会
IF 3.6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-02-18 DOI: 10.1016/S0003-4975(25)00021-9
{"title":"Society Board","authors":"","doi":"10.1016/S0003-4975(25)00021-9","DOIUrl":"10.1016/S0003-4975(25)00021-9","url":null,"abstract":"","PeriodicalId":50976,"journal":{"name":"Annals of Thoracic Surgery","volume":"119 3","pages":"Page A7"},"PeriodicalIF":3.6,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143429363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In Memoriam: David Fullerton, STS Past President and Superb Cardiac Surgeon, Educator, Investigator and Leader (1952 - 2024). 悼念:大卫-富勒顿(David Fullerton),STS 前任主席、杰出的心脏外科医生、教育家、研究者和领导者(1952 - 2024)。
IF 3.6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-02-13 DOI: 10.1016/j.athoracsur.2025.01.028
John Calhoon, Joe Cleveland, William Baumgartner
{"title":"In Memoriam: David Fullerton, STS Past President and Superb Cardiac Surgeon, Educator, Investigator and Leader (1952 - 2024).","authors":"John Calhoon, Joe Cleveland, William Baumgartner","doi":"10.1016/j.athoracsur.2025.01.028","DOIUrl":"https://doi.org/10.1016/j.athoracsur.2025.01.028","url":null,"abstract":"","PeriodicalId":50976,"journal":{"name":"Annals of Thoracic Surgery","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143426702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The future is the present, but not always the past. 未来就是现在,但并不总是过去。
IF 3.6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-02-13 DOI: 10.1016/j.athoracsur.2025.02.001
Aaron Guo, Nahush Ashok Mokadam
{"title":"The future is the present, but not always the past.","authors":"Aaron Guo, Nahush Ashok Mokadam","doi":"10.1016/j.athoracsur.2025.02.001","DOIUrl":"https://doi.org/10.1016/j.athoracsur.2025.02.001","url":null,"abstract":"","PeriodicalId":50976,"journal":{"name":"Annals of Thoracic Surgery","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143426705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enhanced Survival With Surgical Ablation of Atrial Fibrillation During Mitral Valve Surgery. 在二尖瓣手术中通过手术消融心房颤动提高存活率
IF 3.6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-02-12 DOI: 10.1016/j.athoracsur.2025.01.026
John Eisenga, Kyle McCullough, Jasjit Banwait, Timothy George, Kelley Hutcheson, Robert Smith, J Michael DiMaio, Justin Schaffer

Background: Surgical ablation(SA) at the time of isolated mitral valve surgery(MVS) is recommended in patients with preexisting atrial fibrillation(AF). However, SA remains infrequently utilized during MVS with a poorly quantified impact on stroke and survival.

Methods: Medicare claims(2008-2019) were queried to identify beneficiaries with preexisting AF undergoing MVS. All-cause mortality and the post-operative incidence of stroke/transient ischemic attack(TIA) were evaluated as separate endpoints. Overlap propensity score weighting was used to risk-adjust for measured confounding variables. Analyses were repeated using surgeon frequency of SA as an instrumental variable to adjust for unmeasured confounding variables.

Results: From 2008-2019, 41,795 Medicare beneficiaries with a preexisting diagnosis of AF underwent MVS. Surgeons were categorized, with 1,326 infrequently(bottom quartile) performing SA(<30%; 10,364 beneficiaries) and 740 frequently(top quartile) performing SA(≥62%; 10,476 beneficiaries) during MVS. Beneficiaries undergoing MVS with SA("as-treated" analysis) had a risk-adjusted median survival advantage of 0.56[0.33-0.81] years (8.85[8.64-9.04] vs 8.29[8.11-8.47] years, P<0.001 for risk-adjusted survival comparison) compared to those without. Beneficiaries undergoing MVS by frequent SA surgeons("surgeon-preference" analysis) had a risk-adjusted median survival advantage of 0.35[0.05-0.71] years (8.59[8.40-8.85] vs 8.24[7.97-8.40] years, P=0.0015 for risk-adjusted survival comparison) compared to surgeons who infrequently performed SA.

Conclusions: In Medicare beneficiaries with preexisting AF, concomitant SA during MVS is associated with improved survival, as is undergoing surgery by a frequent SA surgeon. When analyzed based on surgeon preference for SA, the magnitude and time-dependent nature of the treatment effect of SA were substantially different compared to the "as-treated" analysis, suggesting that "as-treated" analyses may be subject to bias from unmeasured confounding variables.

背景:对于已有心房颤动(房颤)的患者,建议在进行孤立二尖瓣手术(MVS)时进行手术消融(SA)。然而,在二尖瓣置换术中使用手术消融的情况仍不常见,对中风和存活率的影响也很少量化:方法:查询了医疗保险报销单(2008-2019 年),以确定接受 MVS 的原有房颤受益人。将全因死亡率和术后中风/短暂性脑缺血发作(TIA)发生率作为单独的终点进行评估。采用重叠倾向评分加权法对测量的混杂变量进行风险调整。使用外科医生的SA频率作为工具变量重复分析,以调整未测量的混杂变量:2008-2019 年间,41,795 名已有房颤诊断的医疗保险受益人接受了 MVS。对外科医生进行了分类,其中1326名外科医生很少(最低四分位数)进行SA手术:对于已有心房颤动的医保受益人而言,在 MVS 期间同时进行 SA 与生存率的提高有关,由经常进行 SA 的外科医生进行手术也与生存率的提高有关。根据外科医生对 SA 的偏好进行分析时,SA 治疗效果的程度和时间依赖性与 "按治疗 "分析相比有很大不同,这表明 "按治疗 "分析可能会受到未测量混杂变量的影响。
{"title":"Enhanced Survival With Surgical Ablation of Atrial Fibrillation During Mitral Valve Surgery.","authors":"John Eisenga, Kyle McCullough, Jasjit Banwait, Timothy George, Kelley Hutcheson, Robert Smith, J Michael DiMaio, Justin Schaffer","doi":"10.1016/j.athoracsur.2025.01.026","DOIUrl":"https://doi.org/10.1016/j.athoracsur.2025.01.026","url":null,"abstract":"<p><strong>Background: </strong>Surgical ablation(SA) at the time of isolated mitral valve surgery(MVS) is recommended in patients with preexisting atrial fibrillation(AF). However, SA remains infrequently utilized during MVS with a poorly quantified impact on stroke and survival.</p><p><strong>Methods: </strong>Medicare claims(2008-2019) were queried to identify beneficiaries with preexisting AF undergoing MVS. All-cause mortality and the post-operative incidence of stroke/transient ischemic attack(TIA) were evaluated as separate endpoints. Overlap propensity score weighting was used to risk-adjust for measured confounding variables. Analyses were repeated using surgeon frequency of SA as an instrumental variable to adjust for unmeasured confounding variables.</p><p><strong>Results: </strong>From 2008-2019, 41,795 Medicare beneficiaries with a preexisting diagnosis of AF underwent MVS. Surgeons were categorized, with 1,326 infrequently(bottom quartile) performing SA(<30%; 10,364 beneficiaries) and 740 frequently(top quartile) performing SA(≥62%; 10,476 beneficiaries) during MVS. Beneficiaries undergoing MVS with SA(\"as-treated\" analysis) had a risk-adjusted median survival advantage of 0.56[0.33-0.81] years (8.85[8.64-9.04] vs 8.29[8.11-8.47] years, P<0.001 for risk-adjusted survival comparison) compared to those without. Beneficiaries undergoing MVS by frequent SA surgeons(\"surgeon-preference\" analysis) had a risk-adjusted median survival advantage of 0.35[0.05-0.71] years (8.59[8.40-8.85] vs 8.24[7.97-8.40] years, P=0.0015 for risk-adjusted survival comparison) compared to surgeons who infrequently performed SA.</p><p><strong>Conclusions: </strong>In Medicare beneficiaries with preexisting AF, concomitant SA during MVS is associated with improved survival, as is undergoing surgery by a frequent SA surgeon. When analyzed based on surgeon preference for SA, the magnitude and time-dependent nature of the treatment effect of SA were substantially different compared to the \"as-treated\" analysis, suggesting that \"as-treated\" analyses may be subject to bias from unmeasured confounding variables.</p>","PeriodicalId":50976,"journal":{"name":"Annals of Thoracic Surgery","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143426653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ideal Timing of Coronary Artery Bypass Grafting after Non-ST Elevation Myocardial Infarction.
IF 3.6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-02-11 DOI: 10.1016/j.athoracsur.2025.01.024
Anthony V Norman, Matthew P Weber, Mohamad El Moheb, Alexander M Wisniewski, Raymond J Strobel, Alan Speir, Michael Mazzeffi, Aarathi Manchikalapud, Mark Joseph, Daniel Tang, Ramesh Singh, Mohammed Quader, Jared P Beller, Kenan Yount, Nicholas R Teman

Background: Non-ST elevation myocardial infarction (NSTEMI) patients benefit from revascularization, but guidelines are vague regarding optimal timing. We aimed to identify the ideal timing of coronary artery bypass grafting (CABG) after NSTEMI.

Methods: We examined NSTEMI patients who underwent isolated CABG within 30 days of cardiac catheterization between July 2011-July 2023 using a multicenter regional collaborative. Patients were stratified into three groups: <2 days, 3-7 days, and 8-30 days. Multivariable logistic regression analysis was performed to identify risk factors associated with mortality.

Results: We identified 10,271 CABG patients, of which 3,464 (34%) underwent CABG within <2 days, 5,751 (56%) 3-7 days, and 1056 (10%) 8-30 days. The 3-7 day group had the lowest median Society of Thoracic Surgeons predicted risk of mortality (1.36% vs. 1.35% vs. 2.09%, p<0.001). The <2 day group more frequently presented with left main disease (19% vs. 16% vs. 16%, p<0.001) and cardiogenic shock (5.1% vs. 1.8% vs. 2%, p<0.001). Mean cardiopulmonary bypass time was similar between groups (97 mins vs 97 vs 97, p=0.63). The 3-7 day group had the lowest operative mortality (3.2% vs. 1.8% vs. 4%, p<0.001) and major morbidity (14% vs 11% vs. 16%, p<0.001). After risk-adjustment, the 3-7 day window was associated with decreased mortality compared to <2 days (OR 0.56, 95%CI 0.4-0.78, p<0.001) and 8-30 days (OR 0.51, 95%CI 0.32-0.81, p<0.001).

Conclusions: CABG between 3-7 days after cardiac catheterization for NSTEMI was associated with the lowest risk of mortality. When possible, CABG within this window may afford better outcomes.

{"title":"Ideal Timing of Coronary Artery Bypass Grafting after Non-ST Elevation Myocardial Infarction.","authors":"Anthony V Norman, Matthew P Weber, Mohamad El Moheb, Alexander M Wisniewski, Raymond J Strobel, Alan Speir, Michael Mazzeffi, Aarathi Manchikalapud, Mark Joseph, Daniel Tang, Ramesh Singh, Mohammed Quader, Jared P Beller, Kenan Yount, Nicholas R Teman","doi":"10.1016/j.athoracsur.2025.01.024","DOIUrl":"https://doi.org/10.1016/j.athoracsur.2025.01.024","url":null,"abstract":"<p><strong>Background: </strong>Non-ST elevation myocardial infarction (NSTEMI) patients benefit from revascularization, but guidelines are vague regarding optimal timing. We aimed to identify the ideal timing of coronary artery bypass grafting (CABG) after NSTEMI.</p><p><strong>Methods: </strong>We examined NSTEMI patients who underwent isolated CABG within 30 days of cardiac catheterization between July 2011-July 2023 using a multicenter regional collaborative. Patients were stratified into three groups: <2 days, 3-7 days, and 8-30 days. Multivariable logistic regression analysis was performed to identify risk factors associated with mortality.</p><p><strong>Results: </strong>We identified 10,271 CABG patients, of which 3,464 (34%) underwent CABG within <2 days, 5,751 (56%) 3-7 days, and 1056 (10%) 8-30 days. The 3-7 day group had the lowest median Society of Thoracic Surgeons predicted risk of mortality (1.36% vs. 1.35% vs. 2.09%, p<0.001). The <2 day group more frequently presented with left main disease (19% vs. 16% vs. 16%, p<0.001) and cardiogenic shock (5.1% vs. 1.8% vs. 2%, p<0.001). Mean cardiopulmonary bypass time was similar between groups (97 mins vs 97 vs 97, p=0.63). The 3-7 day group had the lowest operative mortality (3.2% vs. 1.8% vs. 4%, p<0.001) and major morbidity (14% vs 11% vs. 16%, p<0.001). After risk-adjustment, the 3-7 day window was associated with decreased mortality compared to <2 days (OR 0.56, 95%CI 0.4-0.78, p<0.001) and 8-30 days (OR 0.51, 95%CI 0.32-0.81, p<0.001).</p><p><strong>Conclusions: </strong>CABG between 3-7 days after cardiac catheterization for NSTEMI was associated with the lowest risk of mortality. When possible, CABG within this window may afford better outcomes.</p>","PeriodicalId":50976,"journal":{"name":"Annals of Thoracic Surgery","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143416190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Minimally Invasive Valve Surgery for Patients with Infective Endocarditis: A Comparative Study.
IF 3.6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-02-11 DOI: 10.1016/j.athoracsur.2025.01.023
Connor Raikar, Stanley Wolfe, Luigi F Lagazzi, Ali Darehzereshki, Nathan Kister, Lawrence Wei, Vinay Badhwar, J Hunter Mehaffey

Background: Patients with endocarditis frequently require valve surgery, and despite recent growth of minimally invasive cardiac surgery (MICS) for complex valve operations, consensus recommendations still suggest conventional sternotomy.

Methods: Institutional Society of Thoracic Surgeons (STS) Adult Cardiac Surgery Database evaluated all patients undergoing valve surgery for endocarditis (1/2016-3/2024). Patients were stratified by conventional sternotomy vs MICS approach, including hemi-sternotomy, right -thoracotomy, and robotic-assisted mitral/tricuspid/aortic valve surgery. Logistic regression assessed risk-adjusted association with the primary outcomes of STS major morbidity or mortality and MICS approach accounting for all covariates in current STS risk models.

Results: Of 741 patients undergoing valve surgery for endocarditis, median age 37 years, 582 (78.5%) had substance use disorder, 210 (28.3%) redo sternotomies and 166 (22.4%) redo valve operations. MICS was associated with a higher repair rate for mitral valves (76.3% vs 48%, p<0.0001) but lower for tricuspid valve (22.5% vs 44.1%, p<0.0001), with no difference for aortic valves (8.3% vs 7.4%, p=0.372). Prior to risk adjustment, MICS was associated with longer cross clamp times (99 min vs 86 min, p=0.019) but lower incidence of STS major morbidity or mortality (15.4% vs 27.8%, p=0.019). After robust risk adjustment, age (OR 1.1, p=0.008), lung disease (OR 2.2, p=0.010), preoperative creatinine (OR 1.3, p=0.016), valve repair vs replacement (OR 0.17, p=0.002), but not MICS (OR 1.2, p=0.807) were independently associated with STS major morbidity and mortality.

Conclusions: MICS valve surgery for endocarditis appears both safe and effective, with similar repair rates and risk adjusted outcomes to open surgery.

{"title":"Minimally Invasive Valve Surgery for Patients with Infective Endocarditis: A Comparative Study.","authors":"Connor Raikar, Stanley Wolfe, Luigi F Lagazzi, Ali Darehzereshki, Nathan Kister, Lawrence Wei, Vinay Badhwar, J Hunter Mehaffey","doi":"10.1016/j.athoracsur.2025.01.023","DOIUrl":"https://doi.org/10.1016/j.athoracsur.2025.01.023","url":null,"abstract":"<p><strong>Background: </strong>Patients with endocarditis frequently require valve surgery, and despite recent growth of minimally invasive cardiac surgery (MICS) for complex valve operations, consensus recommendations still suggest conventional sternotomy.</p><p><strong>Methods: </strong>Institutional Society of Thoracic Surgeons (STS) Adult Cardiac Surgery Database evaluated all patients undergoing valve surgery for endocarditis (1/2016-3/2024). Patients were stratified by conventional sternotomy vs MICS approach, including hemi-sternotomy, right -thoracotomy, and robotic-assisted mitral/tricuspid/aortic valve surgery. Logistic regression assessed risk-adjusted association with the primary outcomes of STS major morbidity or mortality and MICS approach accounting for all covariates in current STS risk models.</p><p><strong>Results: </strong>Of 741 patients undergoing valve surgery for endocarditis, median age 37 years, 582 (78.5%) had substance use disorder, 210 (28.3%) redo sternotomies and 166 (22.4%) redo valve operations. MICS was associated with a higher repair rate for mitral valves (76.3% vs 48%, p<0.0001) but lower for tricuspid valve (22.5% vs 44.1%, p<0.0001), with no difference for aortic valves (8.3% vs 7.4%, p=0.372). Prior to risk adjustment, MICS was associated with longer cross clamp times (99 min vs 86 min, p=0.019) but lower incidence of STS major morbidity or mortality (15.4% vs 27.8%, p=0.019). After robust risk adjustment, age (OR 1.1, p=0.008), lung disease (OR 2.2, p=0.010), preoperative creatinine (OR 1.3, p=0.016), valve repair vs replacement (OR 0.17, p=0.002), but not MICS (OR 1.2, p=0.807) were independently associated with STS major morbidity and mortality.</p><p><strong>Conclusions: </strong>MICS valve surgery for endocarditis appears both safe and effective, with similar repair rates and risk adjusted outcomes to open surgery.</p>","PeriodicalId":50976,"journal":{"name":"Annals of Thoracic Surgery","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143416193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Annals of Thoracic Surgery
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1